Changes in Hong Kong stocks | Cinda Biotech (01801) has recently been approved for listing and commercialization is imminent

The Zhitong Finance App learned that Cinda Biotech (01801) rose more than 4%. As of press release, it had risen 3.66% to HK$82.2, with a turnover of HK$634 million.

According to the news, on June 27, Cinda Biotech announced that the new drug marketing application (NDA) for the glucagon (GCG) /glucagon-like peptide-1 (GLP-1) dual receptor agonist, has been approved by the China National Drug Administration (NMPA) for long-term weight control in adult obese or overweight patients. Xinermei® is the world's first GCG/GLP-1 dual receptor agonist weight loss drug. Its unique mechanism of action can not only increase weight loss effects, but also directly reduce visceral fat content, bringing comprehensive metabolic benefits, and was rated as one of the top ten most anticipated drugs in the world in 2025 (FIERCE Pharma 2025).

CITIC Construction Investment released a research report stating that Cinda BioMashidu Peptide was approved for listing on June 27, and subsequent commercialization is imminent. In the previous phase III weight loss study, Mashidu peptide showed excellent weight loss effects. After 32 weeks of placebo correction, it also significantly reduced indicators such as liver fat, blood pressure, blood lipids, and blood uric acid, bringing comprehensive benefits to obese people. As the product is soon to be commercialized, many obese people are expected to benefit from Mashidol peptides.